Stocktoria
IGC Pharma, Inc. IGC
IGC Pharma, Inc. (IGC) earns a Piotroski F-score of 3/9 (weak financial health). It does not currently pay a dividend. FY2025 revenue was $1.3M at a -560.3% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Beneish M-score: -3.68 — low (below −2.22 — no manipulation red flag) . A statistical screen for earnings manipulation, not proof — and it doesn't apply to most banks/insurers.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 3/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| IGC | IGC Pharma, Inc. | 3/9 | — | — | — |
| VTGN | Vistagen Therapeutics, Inc. | 2/9 | — | — | — |
| LGVN | Longeveron Inc. | 2/9 | — | — | — |
| NWBO | NORTHWEST BIOTHERAPEUTICS INC | 4/9 | — | — | — |
| SXTC | China SXT Pharmaceuticals, Inc. | 3/9 | 2.19 | — | — |
| RNXT | RenovoRx, Inc. | 2/9 | — | — | — |
| NRXP | NRX Pharmaceuticals, Inc. | 4/9 | — | — | — |
About IGC Pharma, Inc.
IGC Pharma, Inc., a clinical stage pharmaceutical company, develops novel therapeutic candidates for neuropsychiatric and neurodegenerative disorders, with a primary focus on Alzheimer's disease in the United States and Colombia. The company's lead product is IGC-AD1 that is in Phase II clinical trial for the treatment of agitation in dementia due to Alzheimer's. Its pre-clinical stage product candidate includes TGR-63 and IGC-M3 to treat Alzheimer's disease. In addition, the company develops MINT-AD, an AI-driven assistant for healthcare providers. The company was formerly known as India Globalization Capital, Inc. and changed its name to IGC Pharma, Inc. in March 2023. IGC Pharma, Inc. was incorporated in 2005 and is headquartered in Potomac, Maryland.
FAQ
Is IGC financially healthy?
IGC Pharma, Inc.'s Piotroski F-score is 3/9 (8–9 is excellent, 0–3 weak).
Does IGC pay a dividend?
No, IGC Pharma, Inc. does not currently pay a dividend.
How profitable is IGC?
In FY2025, IGC Pharma, Inc. had a net margin of -560.3% and a return on equity of -112.5%.
What is the analyst price target for IGC?
The average Wall-Street price target for IGC Pharma, Inc. is $4.25, about 1386.5% above the recent price, from 2 analysts.
Is IGC a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on IGC Pharma, Inc.: a Piotroski F-score of 3/9. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-03-31. Facts plus Stocktoria's own computed scores — not investment advice.